异甘草酸镁联合胸腺肽α1治疗药物诱导自身免疫性肝炎的临床研究

Clinical study of isoglycyrrhizinate with thymosin α1 in treatment of drug-induced autoimmune hepatitis

目的观察异甘草酸镁联合胸腺肽α1治疗药物诱导自身免疫性肝炎的疗效。方法将86例药物诱导的自身免疫性肝炎患者随机分为3组,A组27例,给予传统治疗;B组31例,给予传统治疗+异甘草酸镁;C组28例,给予传统治疗+异甘草酸镁+胸腺肽α1;3组患者疗程均为4周。结果 A组患者肝功能指标好转,血清肝纤维化指标下降,但与治疗前比较,差异无统计学意义(P>0.05)。B组患者肝功能指标好转,与治疗前比较,差异有统计学意义(P<0.01),血清肝纤维化指标和血清球蛋白水平与治疗前比较,差异无统计学意义(P>0.05)。C组患者肝功能指标、血清肝纤维化指标和血清球蛋白水平下降程度均优于A组和B组(P<0.01)。结论药物诱导自身免疫性肝炎患者,给予异甘草酸镁,同时应用胸腺肽α1调节免疫治疗可有效改善患者肝功能及肝纤维化指标。

Objective To investigate the efficacy and safety of isoglycyrrhizinate and thymosin otl in treatment of drug-induced autoimmune hepatitis. Methods 86 patients with drug-induced autoimmune hepatitis were randomly di- vided into A group （conventional therapy） , B group （conventional therapy ＋ isoglycyrrhizinate） and C group （conven- tional therapy ＋ isoglycyrrhizinate and thymosin otl ）. Results After four weeks treatment, the liver function and he- patic fibrosis in A group were not significantly improved compared with before treatment. The liver function in B group was significantly improved compared with before treatment （P 〈 0.01 ）. But hepatic fibrosis and serum GLB in B group had no gignificant difference compared with before treatment. The hepatic fibrosis, the liver function and GLB in C group were significantly ameliorated compared with A group and B group （P 〈 0.01 ）. Conclusion Isoglycyrrhizinate can rapidly and effectively improve the liver function. If combined with thymosin α1, the therapeutic effect on drug-in- duced autoimmune hepatitis fibrosis and globin would be more manifest.